This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Eli Lilly and Company. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Biography of Krister Bengt Bokvist
Introduction: Krister Bengt Bokvist is an accomplished inventor based in Carmel, Indiana, known for his significant contributions to the field of diabetes treatment. He has developed innovative peptides that have the potential to improve the management of this chronic condition.
Latest Patents: Krister holds a patent for "Peptides and methods for their preparation and use." This invention focuses on peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide-1 receptor (GLP-1-R), while maintaining selectivity over the glucagon receptor (Gluc-R). The patent specifically provides GIP analogs with amino acid substitutions designed to modulate activity for both GIP-R and GLP-1-R.
Career Highlights: Krister has made significant strides in his career, particularly through his work at Eli Lilly and Company. His research and innovations have contributed to advancements in diabetes treatment, showcasing his expertise in peptide technology.
Collaborations: Throughout his career, Krister has collaborated with notable colleagues, including Jorge Alsina-Fernandez and Lili Guo. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in the pharmaceutical field.
Conclusion: Krister Bengt Bokvist is a prominent figure in the realm of diabetes research and peptide innovation. His work continues to impact
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile